Asterias Biotherapeutics, Inc. (AST) Analysts See $-0.15 EPS

March 14, 2018 - By Henry Gaston

 Asterias Biotherapeutics, Inc. (AST) Analysts See $ 0.15 EPS

Analysts expect Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) to report $-0.15 EPS on March, 27.They anticipate $0.03 EPS change or 16.67 % from last quarter’s $-0.18 EPS. After having $-0.15 EPS previously, Asterias Biotherapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 2.56% or $0.05 during the last trading session, reaching $2. About 98,157 shares traded. Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) has risen 4.43% since March 14, 2017 and is uptrending. It has underperformed by 12.27% the S&P500.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company has market cap of $108.30 million. The firm develops therapeutic products in the areas of neurology and oncology. It currently has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

More news for Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) were recently published by:, which released: “Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results …” on March 09, 2018.‘s article titled: “Asterias Biotherapeutics (AST) Reports Update on AST-OPC1 Phase 1/2a Clinical …” and published on February 28, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.